NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$128.5m

NGM Biopharmaceuticals Management

Management criteria checks 2/4

NGM Biopharmaceuticals' CEO is David Woodhouse, appointed in Sep 2018, has a tenure of 5.58 years. total yearly compensation is $5.93M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $179.29K. The average tenure of the management team and the board of directors is 1.3 years and 5.6 years respectively.

Key information

David Woodhouse

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage10.3%
CEO tenure5.6yrs
CEO ownership0.1%
Management average tenure1.3yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

CEO Compensation Analysis

How has David Woodhouse's remuneration changed compared to NGM Biopharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$142m

Sep 30 2023n/an/a

-US$151m

Jun 30 2023n/an/a

-US$170m

Mar 31 2023n/an/a

-US$178m

Dec 31 2022US$6mUS$610k

-US$163m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$125m

Dec 31 2021US$10mUS$580k

-US$120m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$122m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$5mUS$525k

-US$102m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$490k

-US$43m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$4mUS$413k

-US$493k

Compensation vs Market: David's total compensation ($USD5.93M) is above average for companies of similar size in the US market ($USD662.79K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Woodhouse (52 yo)

5.6yrs

Tenure

US$5,933,500

Compensation

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

Leadership Team

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Valerie Pierce
Senior VP4.5yrsUS$2.10m0.022%
$ 28.7k
Hsiao Lieu
Chief Medical Officer & Executive VP5.1yrsUS$2.73m0.017%
$ 22.3k
Jean Frederic Viret
Chief Financial Officer1.3yrsno datano data
Irene Perlich
VP, Corporate Controller & Principal Accounting Officerless than a yearno data0.011%
$ 13.8k
Daniel Kaplan
Chief Scientific Officer1.3yrsno datano data
Mahi Saraf
Director of People & Cultureless than a yearno datano data
Diana Bockus
Head of Business Development1.8yrsno datano data
Arthur Hsu
Senior Director & Head of Biology1.3yrsno datano data
Kara Calhoun
Senior Vice President of CMC & Process Developmentless than a yearno datano data

1.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: NGM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Grant Heidrich
Special Advisorno datano datano data
Arthur Levinson
Special Advisorno datano datano data
David Goeddel
Lead Independent Director5.6yrsUS$270.23k19.87%
$ 25.5m
Michael Brown
Chairman of the Scientific Advisory Boardno datano datano data
Joseph Goldstein
Member of the Scientific Advisory Boardno datano datano data
Roger Perlmutter
Independent Director2.8yrsUS$250.00k0%
$ 0
Shelly Guyer
Independent Director4.3yrsUS$273.09k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno datano datano data
Suzanne Hooper
Independent Director5.7yrsUS$265.00k0.0084%
$ 10.8k
Michael Fischbach
Member of Scientific Advisory Boardno datano datano data

5.6yrs

Average Tenure

67yo

Average Age

Experienced Board: NGM's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/05 20:39
End of Day Share Price 2024/04/05 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NGM Biopharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Paul ChoiGoldman Sachs